Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli

Journal of Industrial Microbiology and Biotechnology

Volumn 41, Issue 6, 2014, Pages 947-956

  Akbari, Vajihe ^a   Mir Mohammad Sadeghi, Hamid ^a   Jafrian Dehkordi, Abbas ^a   Abedi, Daryoush ^a   Chou, C Perry ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF WATERLOO   (Canada)

Author keywords

Breast cancer; Cytoplasmic expression; Escherichia coli; HER2; Single chain variable fragment antibody

Indexed keywords

BACTERIAL PROTEIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PERTUZUMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB;

ARTICLE; BACTERIAL GENETICS; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER CELL; CELL INCLUSION; CELL SURFACE; CYTOPLASM; DRUG TARGETING; ESCHERICHIA COLI; FERMENTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PURIFICATION; RECEPTOR BINDING; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ESCHERICHIA COLI; HUMANS; RECEPTOR, ERBB-2; SINGLE-CHAIN ANTIBODIES;

EID: 84901310169     PISSN: 13675435     EISSN: 14765535     Source Type: Journal    
DOI: 10.1007/s10295-014-1437-0     Document Type: Article

References (53)

1. Abéngozar MA, de Frutos S, Ferreiro S, Soriano J, Perez-Martinez M, Olmeda D, Marenchino M, Cañamero M, Ortega S, Megias D (2012) Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood 119(19):4565-4576
2. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2(2):127-137 (Pubitemid 41039113)
3. Bazley L, Gullick W (2005) The epidermal growth factor receptor family. Endocr Relat Cancer 12(Suppl 1):S17-S27 (Pubitemid 41395411)
4. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M (2009) Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci 106(9):3294-3299
5. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper J, Dodge R, Clarke-Pearson D, Marks P (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50(13):4087-4091 (Pubitemid 20225635)
6. Bird R, Hardman K, Jacobson J, Johnson S, Kaufman B, Lee S, Lee T, Pope S, Riordan G, Whitlow M (1988) Single-chain antigen-binding proteins. Science 242(4877):423
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72(1):248-254
8. Brandt BH, Roetger A, Dittmar T, Nikolai G, Seeling M, Merschjann A, Nofer JR, Dehmer-Möller G, Junker R, Assmann G (1999) c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J 13(14):1939-1949 (Pubitemid 29517624)
9. Bu D, Zhou Y, Tang J, Jing F, Zhang W (2013) Expression and purification of a novel therapeutic single-chain variable fragment antibody against BNP from inclusion bodies of Escherichia coli. Protein Expr Purif 92(2):203-207
10. Chen C, Snedecor B, Nishihara J, Joly J, McFarland N, Andersen D, Battersby J, Champion K (2004) High-level accumulation of a recombinant antibody fragment in the periplasm of Escherichia coli requires a triple-mutant (degP prc spr) host strain. Biotechnol Bioeng 85(5):463-474 (Pubitemid 38268662)
11. Chen L-H, Huang Q, Wan L, Zeng L-Y, Li S-F, Li Y-P, Lu X-F, Cheng J-Q (2006) Expression, purification, and in vitro refolding of a humanized single-chain Fv antibody against human CTLA4 (CD152). Protein Expr Purif 46(2):495-502
12. Cornelis P (2000) Expressing genes in different Escherichia coli compartments. Curr Opin Biotechnol 11(5):450-454
13. Denlinger C, Beeram M, Tolcher A, Goldstein L, Slichenmyer W, Murray J, Mcdonagh C, Andreas K, Moyo V (2010) A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers. J Clin Oncol 28:169
14. Desplancq D, King DJ, Lawson AD, Mountain A (1994) Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3. Protein Eng 7(8):1027-1033 (Pubitemid 24256883)
15. El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli F, Hui P (2009) In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer 102(1):134-143
16. Ferrer M, Chernikova TN, Yakimov MM, Golyshin PN, Timmis KN (2003) Chaperonins govern growth of Escherichia coli at low temperatures. Nat Biotechnol 21(11):1266-1267 (Pubitemid 37356602)
17. Franklin M, Carey K, Vajdos F, Leahy D, de Vos A, Sliwkowski M (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5(4):317-328 (Pubitemid 38482068)
18. Furuta T, Ogawa T, Yamaji H (2012) Production of antibody fragments using the baculovirus-insect cell system. Method Mol Biol (Clifton, NJ) 907:371
19. Guo J, You S, Li L, Zhang Y, Huang J, Zhang C (2003) Construction and high-level expression of a single-chain Fv antibody fragment specific for acidic isoferritin in Escherichia coli. J Biotechnol 102(2):177-189 (Pubitemid 36412163)
20. Hoyer W, Ramm K, Pluckthun A (2002) A kinetic trap is an intrinsic feature in the folding pathway of single-chain Fv fragments. Biophys Chem 96(2-3):273-284 (Pubitemid 34548238)
21. Hudson P, Souriau C (2003) Engineered antibodies. Nat Med 9(1):129-134 (Pubitemid 36098274)
22. Keler T, Graziano RF, Mandal A, Wallace PK, Fisher J, Guyre PM, Fanger MW, Deo YM (1997) Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fcγ receptor type I-expressing effector cells. Cancer Res 57(18):4008-4014 (Pubitemid 27427690)
23. Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marmé A, Korfel A, Jäger M, Lindhofer H, Sommer H (2006) Phase I trial of the trifunctional anti-HER2x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 12(10):3085-3091 (Pubitemid 43837355)
24. Larentis AL, Argondizzo APC, Esteves GdS, Jessouron E, Galler R, Medeiros MA (2011) Cloning and optimization of induction conditions for mature PsaA (pneumococcal surface adhesin A) expression in Escherichia coli and recombinant protein stability during long-term storage. Protein Expr Purif 78(1):38-47
25. Lim K-P, Li H, Nathan S (2004) Expression and purification of a recombinant scFv towards the exotoxin of the pathogen Burk-holderia pseudomallei. J Microbiol 42(2):126-132 (Pubitemid 38952355)
26. Liu M, Wang X, Yin C, Zhang Z, Lin Q, Zhen Y, Huang H (2006) One-step on-column purification and refolding of a single-chain variable fragment (scFv) antibody against tumour necrosis factor α. Biotechnol Appl Biochem 43(3):137-145 (Pubitemid 43344555)
27. Lombardi A, Sperandei M, Cantale C, Giacomini P, Galeffi P (2005) Functional expression of a single-chain antibody specific for the HER2 human oncogene in a bacterial reducing environment. Protein Expr Purif 44(1):10-15 (Pubitemid 41405929)
28. Magalhães PO, Lopes AM, Mazzola PG, Rangel-Yagui C, Penna T, Pessoa A Jr (2007) Methods of endotoxin removal from biological preparations: a review. J Pharm Pharm Sci 10(3):388-404
29. Markiv A, Beatson R, Burchell J, Durvasula RV, Kang AS (2011) Expression of recombinant multi-coloured fluorescent antibodies in gor-/trxB-E. coli cytoplasm. BMC Biotechnol 11(1):117
30. Merk H, Stiege W, Tsumoto K, Kumagai I, Erdmann VA (1999) Cell-free expression of two single-chain monoclonal antibodies against lysozyme: effect of domain arrangement on the expression. J Biochem 125(2):328-333 (Pubitemid 29112298)
31. Moore JT, Uppal A, Maley F, Maley G (1993) Overcoming inclusion body formation in a high-level expression system. Protein Expr Purif 4(2):160-163
32. Nettleship JE, Flanagan A, Rahman-Huq N, Hamer R, Owens RJ (2012) Converting monoclonal antibodies into Fab fragments for transient expression in mammalian cells. Method Mol Biol (Clifton, NJ) 801:137
33. Olafsen T, Tan GJ, Cheung C-W, Yazaki PJ, Park JM, Shively JE, Williams LE, Raubitschek AA, Press MF, Wu AM (2004) Characterization of engineered anti-p185HER-2 (scFv-CH3) 2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 17(4):315-323 (Pubitemid 39093511)
34. Robinson MK, Hodge KM, Horak E, Sundberg ÅL, Russeva M, Shaller C, von Mehren M, Shchaveleva I, Simmons H, Marks JD (2008) Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 99(9):1415-1425
35. Rodríguez-Carmona E, Cano-Garrido O, Dragosits M, Maurer M, Mader A, Kunert R, Mattanovich D, Villaverde A, Vázquez F (2012) Recombinant Fab expression and secretion in Escherichia coli continuous culture at medium cell densities: influence of temperature. Process Biochem 47(3):446-452
36. Rubin I, Yarden Y (2001) The basic biology of HER2. Ann Oncol 12(Suppl 1):S3-S8 (Pubitemid 32750577)
37. Santala V, Lamminmäki U (2004) Production of a biotinylated single-chain antibody fragment in the cytoplasm of Escherichia coli. J Immunol Methods 284(1):165-175 (Pubitemid 38084924)
38. Schmitz KR, Ferguson KM (2009) Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res 315(4):659-670
39. Sheridan C (2012) FDA approves pertuzumab. Nat Biotechnol 30(7):570
40. Sommaruga S, Lombardi A, Salvadè A, Mazzucchelli S, Corsi F, Galeffi P, Tortora P, Prosperi D (2011) Highly efficient production of anti-HER2 scFv antibody variant for targeting breast cancer cells. Appl Microbiol Biotechnol 91(3):613-621
41. Vasconcellos FA, Aleixo PB, Stone SC, Conceição FR, Dellagostin OA, Aleixo JAG (2012) Generation and characterization of new HER2 monoclonal antibodies. Acta Histochem 115(3):240-244
42. Volontè F, Piubelli L, Pollegioni L (2011) Optimizing HIV-1 protease production in Escherichia coli as fusion protein. Microb Cell Fact 10:53
43. Wang H, Dai J, Li B, Fan K, Peng L, Zhang D, Cao Z, Qian W, Zhao J (2008) Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A. Protein Expr Purif 58(1):140-147
44. Weisser NE, Hall JC (2009) Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol Adv 27(4):502-520
45. Welch M, Govindarajan S, Ness JE, Villalobos A, Gurney A, Minshull J, Gustafsson C (2009) Design parameters to control synthetic gene expression in Escherichia coli. PLoS One 4(9):e7002
46. Wickham T, Futch K (2012) A phase I study of MM-302, a HER2-targeted liposomal doxorubicin. Patients with advanced, HER2-positive breast cancer. Cancer Res 72:P5-P18
47. Woërn A, Pluëckthun A (1998) An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly. FEBS Lett 427(3):357-361
48. Woestenenk EA, Hammarström M, van den Berg S, Härd T, Berglund H (2004) His tag effect on solubility of human proteins produced in Escherichia coli: a comparison between four expression vectors. J Struct Funct Genomics 5(3):217-229 (Pubitemid 39030613)
49. Wu X, Zhang L, Zhang J, Zhang C, Zhu L, Shi Y (2008) Recombinant early secreted antigen target 6 protein as a skin test antigen for the specific detection of Mycobacterium tuberculosis infection. Clin Exp Immunol 152(1):81-88
50. Xie L, Hall D, Eiteman M, Altman E (2003) Optimization of recombinant aminolevulinate synthase production in Escherichia coli using factorial design. Appl Microbiol Biotechnol 63(3):267-273 (Pubitemid 38139282)
51. Yazaki P, Kassa T, Cheung C, Crow D, Sherman M, Bading J, Anderson A, Colcher D, Raubitschek A (2008) Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. Nucl Med Biol 35(2):151-158 (Pubitemid 351200040)
52. Yokota T, Milenic D, Whitlow M, Schlom J (1992) Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52(12):3402
53. Zhang T, Wang C, Zhang W, Gao Y, Yang S, Wang T, Zhang R, Qin C, Xia X (2010) Generation and characterization of a fusion protein of single-chain fragment variable antibody against hemagglutinin antigen of avian influenza virus and truncated protamine. Vaccine 28(23):3949-3955